These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 28721105)

  • 1. Prediction of efficacy for conversion from adjunctive therapy to monotherapy with eslicarbazepine acetate 800 mg once daily for partial-onset epilepsy.
    Sunkaraneni S; Passarell JA; Ludwig EA; Fiedler-Kelly J; Pitner JK; Grinnell TA; Blum D
    Clin Pharmacol; 2017; 9():65-72. PubMed ID: 28721105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a historical-control phase III study.
    Jacobson MP; Pazdera L; Bhatia P; Grinnell T; Cheng H; Blum D;
    BMC Neurol; 2015 Mar; 15():46. PubMed ID: 25880756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a randomized historical-control phase III study based in North America.
    Sperling MR; Harvey J; Grinnell T; Cheng H; Blum D;
    Epilepsia; 2015 Apr; 56(4):546-55. PubMed ID: 25689448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population Pharmacokinetics and Exposure-Response Analyses of Eslicarbazepine Acetate Efficacy and Safety in Monotherapy of Partial-Onset Seizures.
    Sunkaraneni S; Ludwig EA; Passarell JA; Blum D; Grinnell T; Fiedler-Kelly J
    J Clin Pharmacol; 2018 Jul; 58(7):927-938. PubMed ID: 29528499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conversion to eslicarbazepine acetate monotherapy: A pooled analysis of 2 phase III studies.
    Sperling MR; French J; Jacobson MP; Pazdera L; Gough M; Cheng H; Grinnell T; Blum D;
    Neurology; 2016 Mar; 86(12):1095-102. PubMed ID: 26911639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety and efficacy following conversion to eslicarbazepine acetate monotherapy in adults with focal seizures.
    Chung S; Sinha SR; Shah A; Stern JM; Cheng H; Jung J; Grinnell T; Blum D
    Epilepsy Res; 2019 Jul; 153():59-65. PubMed ID: 30999260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjunctive eslicarbazepine acetate: A pooled analysis of three phase III trials.
    Biton V; Rogin JB; Krauss G; Abou-Khalil B; Rocha JF; Moreira J; Gama H; Trinka E; Elger CE; Cheng H; Grinnell T; Blum D;
    Epilepsy Behav; 2017 Jul; 72():127-134. PubMed ID: 28575761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures.
    Perucca E; Elger C; Halász P; Falcão A; Almeida L; Soares-da-Silva P
    Epilepsy Res; 2011 Sep; 96(1-2):132-9. PubMed ID: 21680153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of eslicarbazepine acetate monotherapy in patients converting from carbamazepine.
    Pazdera L; Sperling MR; Harvey JH; Sam MC; Strom LA; Blum D; Grinnell T; Cheng H
    Epilepsia; 2018 Mar; 59(3):704-714. PubMed ID: 29450890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exposure-safety and efficacy response relationships and population pharmacokinetics of eslicarbazepine acetate.
    Gidal BE; Jacobson MP; Ben-Menachem E; Carreño M; Blum D; Soares-da-Silva P; Falcão A; Rocha F; Moreira J; Grinnell T; Ludwig E; Fiedler-Kelly J; Passarell J; Sunkaraneni S
    Acta Neurol Scand; 2018 Sep; 138(3):203-211. PubMed ID: 29732549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of eslicarbazepine acetate monotherapy for partial-onset seizures: Experience from a multicenter, observational study.
    Toledano R; Jovel CE; Jiménez-Huete A; Bayarri PG; Campos D; Gomariz EL; Giráldez BG; García-Morales I; Falip M; Agredano PM; Palao S; Prior MJAA; Pascual MRQ; Navacerrada FJ; González FJL; Ojeda J; Sáez AA; Bermejo PE; Gil-Nagel A
    Epilepsy Behav; 2017 Aug; 73():173-179. PubMed ID: 28641170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of titration schedule and maintenance dose on the tolerability of adjunctive eslicarbazepine acetate: An integrated analysis of three randomized placebo-controlled trials.
    Krauss G; Biton V; Harvey JH; Elger C; Trinka E; Soares da Silva P; Gama H; Cheng H; Grinnell T; Blum D
    Epilepsy Res; 2018 Jan; 139():1-8. PubMed ID: 29127848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health-related quality of life in patients treated with eslicarbazepine acetate monotherapy: Pooled analysis from two registered clinical trials.
    Cramer JA; Rajagopalan K; Anastassopoulos KP; Blum D;
    Epilepsy Behav; 2019 Mar; 92():31-35. PubMed ID: 30611005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling and simulations to support dose selection for eslicarbazepine acetate therapy in pediatric patients with partial-onset seizures.
    Sunkaraneni S; Ludwig E; Fiedler-Kelly J; Hopkins S; Galluppi G; Blum D
    J Pharmacokinet Pharmacodyn; 2018 Aug; 45(4):649-658. PubMed ID: 29948795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial.
    Sperling MR; Abou-Khalil B; Harvey J; Rogin JB; Biraben A; Galimberti CA; Kowacs PA; Hong SB; Cheng H; Blum D; Nunes T; Soares-da-Silva P;
    Epilepsia; 2015 Feb; 56(2):244-53. PubMed ID: 25528898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pooled efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: Data from four double-blind placebo-controlled pivotal phase III clinical studies.
    Elger C; Koepp M; Trinka E; Villanueva V; Chaves J; Ben-Menachen E; Kowacs PA; Gil-Nagel A; Moreira J; Gama H; Rocha JF; Soares-da-Silva P
    CNS Neurosci Ther; 2017 Dec; 23(12):961-972. PubMed ID: 29030894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations between seizure severity change and patient characteristics, changes in seizure frequency, and health-related quality of life in patients with focal seizures treated with adjunctive eslicarbazepine acetate: Post hoc analyses of clinical trial results.
    Cramer JA; Colman S; Anastassopoulos KP; Grinnell T; Mehta D; Williams GR
    Epilepsy Behav; 2020 Nov; 112():107312. PubMed ID: 32801102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychiatric and cognitive adverse events: A pooled analysis of three phase III trials of adjunctive eslicarbazepine acetate for partial-onset seizures.
    Andermann E; Biton V; Benbadis SR; Shneker B; Shah AK; Carreño M; Trinka E; Ben-Menachem E; Biraben A; Rocha F; Gama H; Cheng H; Blum D;
    Epilepsy Behav; 2018 May; 82():119-127. PubMed ID: 29604484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of adjunctive eslicarbazepine acetate on serum lipids in patients with partial-onset seizures: Impact of concomitant statins and enzyme-inducing antiepileptic drugs.
    Mintzer S; Wechsler RT; Rogin JB; Gidal BE; Schwab M; Ben-Menachem E; Carreño M; da Silva PS; Moreira J; Li Y; Blum D; Grinnell T
    Epilepsy Res; 2018 Mar; 141():83-89. PubMed ID: 29499473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolerability of adjunctive eslicarbazepine acetate according to concomitant lamotrigine or carbamazepine use: A subgroup analysis of three phase III trials in adults with focal (partial-onset) seizures.
    Abou-Khalil B; Klein P; Shah A; Ryvlin P; Specchio LM; Gama H; Rocha F; Blum D; Grinnell T; Cheng H; Jung J
    Epilepsy Res; 2018 Nov; 147():80-86. PubMed ID: 30278294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.